Correlia Biosystems
DefunctYC W18San Francisco, US · Delaware corporation · 16 employees · 8 known investors
Find your way into Correlia Biosystems
812 people in our graph share verified history with the Correlia Biosystems team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Kursad Araz · together at Cornell (overlapped)
knows the team · via Cornell
knows the team · via UC Berkeley
knows the team · via University of Florida
×6knows the team · via Y Combinator
×2knows the team · via Boğaziçi University
Correlia Bio develops the PIXI platform, a benchtop automated immunoassay system that uses proprietary microfluidic gel technology to quantify proteins from samples as small as 1 uL. Aimed at pharmaceutical and proteomics researchers, it offers a faster alternative to traditional ELISA for protein measurement in laboratory workflows.
BiotechDeep TechHardwareHealthtechMedical DevicesLab-on-a-chipMicrofluidicsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (W18)
AA
Akwasi AporiinCo-founder
KA
Kursad ArazinCo-Founder & CTO2013–2025Kursad Araz is founder and CTO of Correlia Biosystems, where he leads development of the PIXI platform for automated protein quantification. His background spans hardware and software product development, with experience across R&D, assay design, and team leadership in laboratory instrumentation.
ST
Samuel TiainFounderSamuel Tia is a bioengineer with experience in product development, scale-up, and manufacturing. He has worked with customers on biotechnology applications and has built and managed product R&D and manufacturing teams.
Investors · 8
Beresford VenturesOrlando
Blue Bear VenturesSan Francisco · $100K – $400K
Cota CapitalSan Francisco
Pallasite VenturesVancouver · $100K – $1.5M
Pangaea Ventures Us Inc.Vancouver · $500K – $1.5M
Y CombinatorSan Francisco · $500K
Neotribe VenturesreportedMenlo Park · $250K – $2M
The Regents of the University of Californiareported
Reported raises · per SEC filings
Form D private placements$10.8M disclosed across 2 rounds · 2020–2023
▶$1.3MraisedMay 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kittu KolluriDirector
- Kursad ArazDirector
- Akwasi AporiExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $1.3M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.6MraisedOct 2020 · 41 investors · BiotechnologyRule 506(b)
▶$9.6MraisedOct 2020 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Akwasi AporiExecutive Officer, Director
- Samuel TiaDirector
- Offering amount
- $9.6M
- Amount sold
- $9.6M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Fortis Life Sciences5 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Antlia Bioscience, Inc.5 shared keywordsAntlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.
Intellia Therapeutics5 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
IQVIA4 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Ancilia Bio4 shared keywordsAncilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).
Genialis3 shared keywordsGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
Eli Lilly3 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Earli3 shared keywordsEarli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells. The company focuses on oncology diagnostics and therapeutics for cancer patients.
Companies competing with Correlia Biosystems for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Correlia Biosystems do?
- Correlia Bio develops the PIXI platform, a benchtop automated immunoassay system that uses proprietary microfluidic gel technology to quantify proteins from samples as small as 1 uL. Aimed at pharmaceutical and proteomics researchers, it offers a faster alternative to traditional ELISA for protein measurement in laboratory workflows.
- Who founded Correlia Biosystems?
- Correlia Biosystems was founded by Akwasi Apori, Kursad Araz, Samuel Tia.
- Who are Correlia Biosystems's investors?
- Correlia Biosystems's investors include Beresford Ventures, Blue Bear Ventures, Cota Capital, Pallasite Ventures, Pangaea Ventures Us Inc., Y Combinator, Neotribe Ventures, The Regents of the University of California.
- How much funding has Correlia Biosystems raised?
- Correlia Biosystems has disclosed $10.8M raised across 2 rounds.
- Where is Correlia Biosystems headquartered?
- Correlia Biosystems is headquartered in San Francisco, US.